Intellia Therapeutics NTLA
$10.00 +$0.48 (+5.04%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.00 +0.01%
Open$9.34
Prev close$9.52
Day range$9.30 – $10.40
Volume15.19M
Market cap$1.40B
P/E (TTM)–
Dividend yield–
NTLA Stock News
Headlines matching Intellia Therapeutics or the NTLA ticker, most recent first.
- Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target Positive
- H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
- Intellia Therapeutics | 8-K: Current report
- Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13
- Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
- Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating
- Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.
- BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17 Negative
- CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
- Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9
- Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24
- A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25
- JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29
- Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15
- Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9 Negative
No comments yet — be the first to weigh in on NTLA.
Sign in to join the discussion.